O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications
Ovarian cancer is a prevalent malignancy among women, often associated with a poor prognosis. Post-translational modifications (PTMs), particularly O-GlcNAcylation, have been implicated in the progression of ovarian cancer. Emerging evidence indicates that dysregulation of O-GlcNAcylation contribute...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Translational Oncology |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523324003449 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846136478646665216 |
|---|---|
| author | Lu Xia Jie Mei Min Huang Dandan Bao Zhiwei Wang Yizhe Chen |
| author_facet | Lu Xia Jie Mei Min Huang Dandan Bao Zhiwei Wang Yizhe Chen |
| author_sort | Lu Xia |
| collection | DOAJ |
| description | Ovarian cancer is a prevalent malignancy among women, often associated with a poor prognosis. Post-translational modifications (PTMs), particularly O-GlcNAcylation, have been implicated in the progression of ovarian cancer. Emerging evidence indicates that dysregulation of O-GlcNAcylation contributes to the initiation and malignant progression of ovarian cancer. This review discusses the potential role of O-GlcNAcylation in ovarian tumorigenesis, with a focus on its regulation of various cellular signaling pathways, including p53, RhoA/ROCK/MLC, Ezrin/Radixin/Moesin (ERM), and β-catenin. This review also emphasizes the O-GlcNAcylation of critical proteins in ovarian cancer, such as SNAP-23, SNAP-29, E-cadherin, and calreticulin. Additionally, the potential of O-GlcNAcylation to enhance immunotherapy for ovarian cancer patients is explored. Several compounds targeting OGT and OGA in ovarian cancer are also highlighted. Targeting the dynamic and versatile nature of O-GlcNAcylation could undoubtedly contribute to more effective treatments and improved outcomes for ovarian cancer patients. |
| format | Article |
| id | doaj-art-8fa8c805550f4bf3acb542281d7c8c67 |
| institution | Kabale University |
| issn | 1936-5233 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Translational Oncology |
| spelling | doaj-art-8fa8c805550f4bf3acb542281d7c8c672024-12-09T04:27:15ZengElsevierTranslational Oncology1936-52332025-01-0151102220O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implicationsLu Xia0Jie Mei1Min Huang2Dandan Bao3Zhiwei Wang4Yizhe Chen5Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, ChinaDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, ChinaDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, ChinaDepartment of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, ChinaCorresponding authors.; Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, ChinaCorresponding authors.; Department of Obstetrics and Gynecology, The Second Affiliated Hospital of Wenzhou Medical University, Wenzhou 325027, ChinaOvarian cancer is a prevalent malignancy among women, often associated with a poor prognosis. Post-translational modifications (PTMs), particularly O-GlcNAcylation, have been implicated in the progression of ovarian cancer. Emerging evidence indicates that dysregulation of O-GlcNAcylation contributes to the initiation and malignant progression of ovarian cancer. This review discusses the potential role of O-GlcNAcylation in ovarian tumorigenesis, with a focus on its regulation of various cellular signaling pathways, including p53, RhoA/ROCK/MLC, Ezrin/Radixin/Moesin (ERM), and β-catenin. This review also emphasizes the O-GlcNAcylation of critical proteins in ovarian cancer, such as SNAP-23, SNAP-29, E-cadherin, and calreticulin. Additionally, the potential of O-GlcNAcylation to enhance immunotherapy for ovarian cancer patients is explored. Several compounds targeting OGT and OGA in ovarian cancer are also highlighted. Targeting the dynamic and versatile nature of O-GlcNAcylation could undoubtedly contribute to more effective treatments and improved outcomes for ovarian cancer patients.http://www.sciencedirect.com/science/article/pii/S1936523324003449OGAOGTPTMOvarian cancerO-GlcNAcylationImmunotherapy |
| spellingShingle | Lu Xia Jie Mei Min Huang Dandan Bao Zhiwei Wang Yizhe Chen O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications Translational Oncology OGA OGT PTM Ovarian cancer O-GlcNAcylation Immunotherapy |
| title | O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications |
| title_full | O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications |
| title_fullStr | O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications |
| title_full_unstemmed | O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications |
| title_short | O-GlcNAcylation in ovarian tumorigenesis and its therapeutic implications |
| title_sort | o glcnacylation in ovarian tumorigenesis and its therapeutic implications |
| topic | OGA OGT PTM Ovarian cancer O-GlcNAcylation Immunotherapy |
| url | http://www.sciencedirect.com/science/article/pii/S1936523324003449 |
| work_keys_str_mv | AT luxia oglcnacylationinovariantumorigenesisanditstherapeuticimplications AT jiemei oglcnacylationinovariantumorigenesisanditstherapeuticimplications AT minhuang oglcnacylationinovariantumorigenesisanditstherapeuticimplications AT dandanbao oglcnacylationinovariantumorigenesisanditstherapeuticimplications AT zhiweiwang oglcnacylationinovariantumorigenesisanditstherapeuticimplications AT yizhechen oglcnacylationinovariantumorigenesisanditstherapeuticimplications |